Compare MGM Resorts International (MGM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs Vertex Pharmaceuticals Incorporated — how do they compare? MGM Resorts International trades at $43.5 (market cap $10.91B), while Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 12.2× MGM Resorts International's market cap, and MGM Resorts International pays a 0.03% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| MGM | VRTX | |
|---|---|---|
Market Cap | $10.91B | $132.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $529.65 |
52-Week Low | $30.72 | $376.62 |
Enterprise Value | $38.21B | $126.92B |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $44.47, down 0.51% on the day, with a bearish technical signal and neutral oscillators. The company reported record Q2 2026 revenue but missed earnings estimates, with net income margin at 2.4% and ROE at 15.44%. Recent news includes a potential acquisition investigation and BetMGM's expansion in Canada, while cash flow trends show improving net cash flow projections for 2026.
Outlook is mixed: analyst consensus leans neutral with a $51.14 price target, but risks include regulatory scrutiny and competitive pressures. The stock offers value with a P/S of 0.66, but investors should weigh earnings volatility and debt levels against growth in digital and Las Vegas operations.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
